Genetic analysis of ovarian microcystic stromal tumor

Huge Ovarian Microcystic Stromal Tumor Presenting As Acute Abdomen in a Patient With Familial Adenomatous Polyposis: A Case Report With Magnetic Resonance Imaging Findings

Microcystic stromal tumors (MCST) are rare sex cord-stromal tumors with distinctive microcystic features and stromal tumor immunophenotypes. Few reports have discussed MCST from the perspective of magnetic resonance imaging (MRI). In this report, we describe the MRI findings of MCST, review our case, and discuss it based on previous reports. A 24-year-old female with a history of familial adenomatous polyposis (FAP) presented to the emergency department with complaints of lower abdominal pain. A plain abdominal computed tomography scan revealed a huge ovarian tumor measuring 19 cm. MRI revealed an isointense ovarian tumor on T1-weighted images and a heterogeneous high signal intensity on T2-weighted images. Contrast-enhanced MRI demonstrated enhancement confined to the capsular structures. Based on the tumor size and MRI findings, malignancy could not be definitively excluded. However, considering the clinical presentation, a diagnosis of tumor infection was made, and an open adnexectomy was subsequently performed. Pathological examination confirmed the diagnosis of MCST, and the patient's condition progressed without apparent recurrence one year after surgery. In previous reports, MCST has been associated with FAP, and almost all cases were benign. Patients diagnosed with FAP can reduce the risk of acute abdominal pain by using less invasive treatments, as long as they keep up with regular checkups and screenings.

A 46-Year-Old Woman with Primary Infertility and a Diagnosis of Microcystic Stromal Tumor of the Ovary Confirmed by Histology and Gene Sequencing: A Case Report and Review of the Literature

Patient: Female, 46-year-old

Final Diagnosis: Microcystic stromal tumor of the ovary

Symptoms: Abdominal pain • vaginal bleeding

Medication: —

Clinical Procedure: —

Specialty: Pathology

Ovarian microcystic stromal tumor with omental metastasis: the first case report and literature review

Background

Microcystic stromal tumor (MCST) of the ovary is an extremely rare subtype of sex cord-stromal neoplasm first described by Irving and Young in 2009. Tumors from all previously reported cases (fewer than 40 total) were benign, but one was a case of ovarian MCST that reoccurred.

Case presentation

Herein, we present a unique single case of ovarian MCST with omental metastasis in a 47-year-old Chinese female along with its histologic and immunohistochemical profile and genetic alterations. The tumor exhibited the previously described classic microscopic features and immunoprofiles of MCST. The tumorlet in the omentum presented the same histological structures and characteristically expressed β-catenin protein (localized in the nucleus). Molecular analysis identified a point mutation (c.98C > G) in exon 3 of CTNNB1.

Conclusions

To the best of our knowledge, no such report has been documented for ovarian MCST with omental metastasis. The study may provide new insights into the tumor biology of MCST and provide a better understanding of this rare entity.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13048-021-00812-1.

Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management

Sex cord stromal-tumors are rare tumors of the ovary that include numerous tumor subtypes of variable histological features and biological behavior. Surgery is the main therapeutic modality for the management of these tumors, while chemotherapy and hormonal therapy may be used in some patients with progressive and recurrent tumors. Several studies investigated molecular changes in the different tumor types. Understanding molecular changes underlying the development and progression of sex cord-stromal tumors provides valuable information for diagnostic and prognostic biomarkers and potential therapeutic targets for these tumors. In this review, we provide an update on the clinical presentation, molecular changes, and management of sex cord-stromal tumors.

The hallmarks of ovarian cancer: proliferation and cell growth

Epithelial ovarian cancer (EOC) is a heterogeneous group of diseases with distinct biological and clinical behaviour. Despite the differences between them, the capability of tumour cells to continuously proliferate and avoid death is maintained among histotypes. This ability is the result of alterations at different levels, causing the deregulation of cell cycle and proliferative-related pathways. Even if the leading role is played by RB and TP53, changes in other molecular pathways are involved in the development of EOC. This ability can be exploited to generate in vitro and in vivo models resembling the conditions of tumour development in a patient. In vivo models, such as patient-derived xenografts (PDX) or genetically engineered mouse models (GEMM), represent a fundamental tool in the study of the molecular mechanisms implicated in each EOC biotype for testing new therapeutic approaches. Herein we describe the major proliferation-related pathways and its disruption found in EOC and how these features can be used to establish in vivo models for translational research.

•

Epithelial ovarian cancer (EOC) molecular biotypes are defined by distinct biology and clinical behaviour.

•

Sustained proliferation and resistance to cell death mechanisms characterised tumour cells.

•

RB and TP53 tumour-suppressor genes are highly implicated in EOC pathogenesis.

•

In vitro and in vivo models have a key role in the study of molecular mechanisms involved in EOC pathogenesis.

•

Development of animal models that mimic disease features constitute essential tools for new drugs testing.

Ovarian Microcystic Stromal Tumor: A Case Report and Literature Review

Background: Microcystic stromal tumor is a recently described subtype of ovarian tumor characterized by microcystic pattern and diffuse immunoreactivity for CD10, vimentin, and β-catenin and negative for EMA. However, its diagnostic criterion and standard treatment remain unclear. Case presentation: We report a rare case of a left side microcystic stromal tumor with diameter about 7 cm in a 25-year-old female and summarize all cases of MCST reported in this study. The present patient underwent left ovarian tumor resection. Generally, the tumor was solid and cystic mixed. Immunohistochemically, the tumor was expressed CD10, WT1, cyclin D1 and vimentin, and nuclear immunoreactivity for β-catenin but negative for α-inhibin, calretinin, CK AE1/AE3, PLAP, SALL-4, CK7, P53, EMA, CD99, AFP, desmin, CgA, E-cadherin, and melanA. Conclusion: Unilateral ovary, solid-cystic, and a larger than 4-8 cm pelvic mass without serious abdominal pain are its clinical features. The immunophenotype of vimentin+/CD10+/WT-1+/β-catenin+(nuclei)/cyclin D1+ is supportive of diagnosis. For these patients, unilateral oophorectomy dissection could be selected.

Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance

Ovarian cancers represent the deadliest among gynecologic malignancies and are characterized by a hierarchical structure with cancer stem cells (CSCs) endowed with self-renewal and the capacity to differentiate. The Wnt/β-catenin signaling pathway, known to regulate stemness in a broad spectrum of stem cell niches including the ovary, is thought to play an important role in ovarian cancer. Importantly, Wnt activity was shown to correlate with grade, epithelial to mesenchymal transition, chemotherapy resistance, and poor prognosis in ovarian cancer. This review will discuss the current knowledge of the role of Wnt signaling in ovarian cancer stemness, epithelial to mesenchymal transition (EMT), and therapy resistance. In addition, the alleged role of exosomes in the paracrine activation of Wnt signaling and pre-metastatic niche formation will be reviewed. Finally, novel potential treatment options based on Wnt inhibition will be highlighted.

Ovarian microcystic stromal tumors: clinical, radiological, and pathological studies of two cases

We observed two unusual cases of ovarian microcystic stromal tumors (MST). These two patients had no obvious clinical symptoms, and the imaging findings were separately diagnosed as cystic teratoma and ovarian malignant tumors. Significantly, during the operation, none of the pathologists considered the possibility of MST. The two cases showed similar morphological and immunophenotypic characteristics: some nests were made up of microcysts with round or oval shapes, and the cavity was bright and empty. In some areas, the cell nests of micro cysts were not obvious and were identified as solid cell nests. The tumor cells contained eosinophilic cytoplasms and neutral nuclei. Mitotic figures were rare. Immunohistochemistry indicated that the tumor cells were all positive for CD10, vimentin, WT1, and β-catenin, but negative for Cytokeratin, α-inhibin, CD99, ER, PR, S-100, EMA, CD56, CgA, Syn, Pax-8, Desmin, SMA, and calretinin. The Ki67 index was less than 5%. Based on the above characteristics, a diagnosis of ovarian MST was made after the operation. The final repeated CT scan revealed no recurrence during the post-surgical course. Here the clinical, radiological and pathological characteristics of these two cases diagnosed as ovarian MST are presented in order to help avoid future misdiagnosis and over-treatment.

Ovarian microcystic stromal tumor: Radiologic-pathologic correlation

Ovarian microcystic stromal tumor (MST) is characterized by microcysts, solid cellular regions with lobulated growth, and collagenous or fibrous stroma forming hyaline plaques. While several reports have evaluated the unique pathologic and immunohistochemical profile of these tumors, there has been limited description of the radiologic findings of ovarian microcystic stromal tumor in the literature. We present a case of a 66 year old female who presented for evaluation of a new cystic pelvic mass found to have ovarian microcystic stromal tumor. To our knowledge, this is one of the first reports to evaluate the radiologic features associated with this tumor. An enhanced understanding of the correlation between imaging appearance and specific histopathologic findings may aid in the early recognition of this rare neoplasm.

Microcystic Stromal Tumor of Testicle: First Case Report and Literature Review

Microcystic stromal tumor (MCST) is a rare subtype of sex cord-stromal neoplasm. Tumors from all 31 previously reported cases were located in the ovary. Herein, we present a unique case of a right-side testicular tumor in a 33-year-old Chinese male. The tumor is composed of predominantly lobulated cellular nodules separated by hyalinized fibrous stroma and they expressed CD10, β-catenin (nuclear), and cyclin D1. Molecular analysis identified a point mutation (c.110C>G) in exon 3 of CTNNB1. The histopathological features, immunohistochemistry profiles, and molecular analysis of this tumor were consistent with MCST of the ovary. Therefore, a diagnosis of MCST of the right testicle was determined. To the best of our knowledge, this is the first case of MCST occurring in the testicles. The study may provide new insights to the tumor biology of MCST and a better understanding of this rare entity.